EP1049471A1 - Compositions et methodes pour le traitement de la dermatite atopique, de l'angiooedeme et d'autres affections par l'emploi d'antihistaminiques et de glucocorticosteroides - Google Patents

Compositions et methodes pour le traitement de la dermatite atopique, de l'angiooedeme et d'autres affections par l'emploi d'antihistaminiques et de glucocorticosteroides

Info

Publication number
EP1049471A1
EP1049471A1 EP99912236A EP99912236A EP1049471A1 EP 1049471 A1 EP1049471 A1 EP 1049471A1 EP 99912236 A EP99912236 A EP 99912236A EP 99912236 A EP99912236 A EP 99912236A EP 1049471 A1 EP1049471 A1 EP 1049471A1
Authority
EP
European Patent Office
Prior art keywords
composition
allergic
substituted
antihistamine
glucocorticoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99912236A
Other languages
German (de)
English (en)
Inventor
Sergio Ulloa Lugo
Jose Villacampa Ramos
Sergio Morales Arellano
Olivier Michel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP1049471A1 publication Critical patent/EP1049471A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention generally relates to compositions and methods for treating atopic dermatitis, angioedema, urticaria, allergic rhinitis and other such disorders. It specifically discloses compositions comprising therapeutically effective amounts of antihistamines such as, for example, loratadine, and glucocorticoids such as, for example, betamethasone, for such treatment.
  • antihistamines such as, for example, loratadine
  • glucocorticoids such as, for example, betamethasone
  • Atopic dermatitis is a chronic, itching, superficial inflammation of the skin, usually found in individuals with a history of allergic disorders. (The Merck Manual of Diagnosis and Therapy, D. Holvey ed., published by Merck & Co., Inc., Rahway,
  • Angioedema and urticaria are local wheals and erythema in the dermis and can be due to causes such as, for example, drug allergy, insect bites and the like, ibid, page 241.
  • Atopic dermatitis is generally managed by applying ointments or pastes of topical corticosteroids. Itching is generally relieved by antihistamines, often in large doses. Initially useful medicaments may generally become ineffective and must be replaced. Acute urticaria is often managed by oral antihistamines; corticosteroid treatment may be occasionally necessary particularly when associated with angioedema.
  • Topical corticosteroids are generally of no value.
  • Products containing a combination of a steroid and an antihistamine are known and available.
  • a product containing chlorfeniramine maleate and paramethasone is available under the tradename DILARMINE ® from Roche Pharmaceuticals, Nutley, New Jersey.
  • DILARMINE ® from Roche Pharmaceuticals, Nutley, New Jersey.
  • the antihistamines in such products are typically sedating. There may be situations where sedating antihistamines are not acceptable.
  • compositions and methods of treatment for diseases such as atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders.
  • diseases such as atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders.
  • compositions and methods of treatment for such diseases using an effective amount of a combination of one or more antihistamines, which are substantially non-sedating, with one or more glucocorticoids.
  • compositions to treat diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders.
  • diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders.
  • the composition comprises in combination: (i) a therapeutically effective amount of one or more substantially non-sedating antihistamines or a pharmaceutically acceptable salt or solvate of such antihistamine(s) and (ii) a therapeutically effective amount of one or more glucocorticoid or a suitable derivative thereof.
  • the present invention additionally discloses a method for the treatment of the above-noted diseases in a mammalian organism in need of such treatment, such treatment comprising administering a pharmaceutical composition described above.
  • antihistamines useful in the practice of the present invention correspond to the general Formula I:
  • X represents a halogen atom or a hydrogen atom
  • Y represents hydrogen, -COORi or -SO 2 R 2
  • Ri represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic ring
  • R 2 represents a substituted or unsubstituted cycloalkyl group, or substituted or unsubstituted aryl group.
  • substituted refers to appropriate substitution with moieties such as, for example, alkyl, aryl, aralkyl, alkylaryl, cycloalkyl, heterocyclic, halogen, ester, amide, ether, carbonyl, sulfonyl and the like.
  • the compounds of Formula I embrace optical isomers and mixtures thereof, racemic mixtures, enol forms and other such modifications.
  • Preferred compounds belonging to Formula I are those in which X is a halogen atom or a hydrogen atom, and Y is hydrogen or -COORi, where Ri is defined above. More particularly preferred compounds of this class are when X is Cl and Ri, is carboethoxy
  • the compounds of Formula I can be prepared in accordance with processes known in the art, for example, that disclosed in U.S. Patents 3,326,924 and 4,282,233.
  • DCL is described, for example, in U.S. Patent 4,659,716 and is a metabolic derivative of loratadine.
  • Glucocorticoids generally belong to a class of steroid hormones that are synthesized by the adrenal cortex of vertebrates and have anti-inflammatory activity. Many are well known.
  • the glucocorticoids useful in the practice of the present invention include, for example, prednisolone, prednisone, betamethasone, dexamethasone, fluoromethalone, medrysone, triamcinolone, hydrocortisone, prednicarbate, deflazacort, halomethasone, tixocortol, predinylidene (21- diethylaminoacetate), prednival, paramethasone, methylprednisolone, meprednisone, mazipredone, isoflupredone, halopredone acetate, halcinonide, formocortal, flurandrenolide, fluprednisolone, fluprednine acetate, fluperolone acetate, fluocor
  • glucocorticoids include betamethasone, prednisolone, prednisone, flumethasone and hydrocortisone. Most preferred is betamethasone. Loratadine has been extensively studied for its antihistaminic effects and is considered to be a safe antihistamine as a H t antagonist. It is also considered to be an antihistamine without clinically significant sedative effects. It has also been proven to be safe and effective for the treatment of several respiratory and dermatologic allergic diseases. Betamethasone (Formula II) is a synthetic fluorinated derivative of hydrocortisone and has antiinflammatory properties. Betamethasone has been
  • the present invention generally discloses novel pharmaceutical compositions comprising a substantially non-sedating antihistamine and a glucocorticoid. Additionally, there may be other optional ingredients present such as, for example, a pharmaceutically acceptable carrier. Still additional ingredients may also be present, especially depending on the form of administration of the pharmaceutical composition, as detailed later.
  • the antihistamine or its pharmacologically acceptable salt or solvate is generally present in the composition in about 2-20 milligrams per dosage, preferably in about 2-10 milligrams and typically in about 3-7 milligrams.
  • the glucocorticoid is generally present in the composition in about 0.02-1 milligram per dosage, preferably in about 0.02-0.8 milligrams and typically in about 0.03-0.5 milligram.
  • the weight ratio of the glucocorticoid and antihistamine is in the range between about 1 : 100 and 1 :10.
  • a pharmaceutically acceptable carrier (which includes diluents, excipients or carrier materials) may also be present in the composition.
  • the carrier is suitably selected with respect to the intended form of administration, i.e. oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, solutions, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices.
  • the active ingredients i.e., the antihistamine and the glucocorticoid
  • any oral non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, ethyl alcohol
  • suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
  • Suitable lubricants that may be mentioned for use in these dosage forms include, for example, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like.
  • Disintegrants include starch, methylcellulose, guar gum and the like.
  • Disinfectants include benzalkonium chloride and the like. Sweetening and flavoring agents and preservatives as well as other ingredients such as, for example, sodium croscarmellose, may also be included where appropriate.
  • the present invention discloses a method of preparing a composition for use in the treatment of diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders, with the composition comprising a therapeutically effective amount of one or more substantially non-sedating antihistamines, or a pharmaceutically acceptable salt or solvate of such antihistamine, and one or more therapeutically effective glucocorticoid, optionally in combination with a pharmaceutically acceptable carrier.
  • diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis
  • the present invention discloses a method of administering an effective treatment for diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders, the administration comprising administering a pharmaceutical composition described above.
  • the pharmaceutical compositions of the present invention can be administered depending upon the patient's age, sex, weight and severity of the condition being treated.
  • the human oral dosage form containing the antihistamine and the carrier can be administered 1 or 2 times per day.
  • this invention discloses a method for the treatment of diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders in a mammalian organism in need of such treatment, such treatment comprising administering a therapeutically effective amount of one or more substantially non-sedating antihistamines, or a pharmaceutically acceptable salt or solvate of such antihistamine, and one or more therapeutically effective glucocorticoid, optionally in combination with a pharmaceutically acceptable carrier.
  • diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrho
  • compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects.
  • Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
  • Dosage form - refers to composition containing the antihistamine, the glucocorticoid and optionally a carrier formulated into a delivery system, i.e., tablet, capsule, oral gel, powder for constitution or suspension in association with inactive ingredients.
  • a delivery system i.e., tablet, capsule, oral gel, powder for constitution or suspension in association with inactive ingredients.
  • Capsule - refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredients and optionally the carrier.
  • Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.
  • Tablet- refers to a compressed or molded solid dosage form containing the active ingredients with suitable diluents.
  • the tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction.
  • Oral gels refers to the active ingredients and the carrier dispersed or solubilized in a hydrophilic semi-solid matrix.
  • Powders for constitution refers to powder blends containing the active ingredients and the carrier and suitable diluents which can be suspended in water or juices.
  • Diluent - refers to substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potato; and celluloses such as microcrystalline cellulose. The amount of diluent in the composition can range from about 2 to about 98% by weight of the total composition.
  • Disintegrants refers to materials added to the composition to help it break apart (disintegrate) and release the medicaments.
  • Suitable disintegrants include starches; "cold water soluble" modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as croscarmellose sodium; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures.
  • the amount of disintegrant in the composition can range from about 1 to about 15% by weight of the composition.
  • Binders - refers to substances that bind or "glue” powders together and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation.
  • Binders add cohesive strength already available in the diluent or bulking agent.
  • Suitable binders include sugars such as sucrose; starches derived from wheat, corn, rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate; cellulosic materials such as cellulose, methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate.
  • the amount of binder in the composition can range from about 2 to about 98% by weight of the composition.
  • Lubricant - refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, to release from the mold or die by reducing friction or wear.
  • Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and d'1-leucine. Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press. The amount of lubricant in the composition can range from about 0.05 to about 5% by weight of the composition.
  • Suitable glidents include silicon dioxide and talc.
  • the amount of glident in the composition can range from about 0.1 % to about 5% by weight of the total composition.
  • Coloring agents - excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent can vary from about 0.1 to about 5% by weight of the composition.
  • Bioavailability - refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control, as well as to topical bioavailability.
  • Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures.
  • the phrase "therapeutically effective amount” means that amount of the active ingredients which provides a therapeutical benefit in the treatment or management of the diseases stated above by the present inventive composition.
  • a prophylactic or therapeutic dose of the active ingredients in the acute or chronic management of the targeted disease or condition will vary with the severity of the condition to be treated and the route of administration.
  • the dose, and perhaps the dose frequency will also vary according the age, body weight, and response of the individual patient. Suitable total daily dose ranges can be readily determined by those skilled in the art.
  • the dose may be administered in single or divided doses orally, topically, transdermally, or locally by inhalation. It is further recommended that children, patients aged over 65 years, and those with impaired renal or haptic function initially receive low doses, and that they then be titrated based on individual response(s) or blood level(s).
  • any suitable route of administration may be employed for providing the patient with an effective dosage of the active ingredients according to the methods of the present invention.
  • Some such routes are, for example, oral, intraoral, rectal, parenteral, epicutaneous, transdermal, subcutaneous, intramuscular, intranasal, sublingual, intradural, intraocular, intrarespiratory, oral or nasal inhalation and the like.
  • Oral administration is preferred.
  • pharmaceutically acceptable salt refers to a salt prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids or bases or organic acids or bases.
  • organic acids examples include hydrochloric, hydrobromic, hydriodic, sulfuric, and phosphoric.
  • Appropriate organic acids may be selected, for example, from aliphatic, aromatic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, glucuronic, maleic, furoic, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, benzenesulfonic, stearic, sulfanilic, algenic, and galacturonic.
  • inorganic bases include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc.
  • Appropriate organic bases may be selected, for example, from N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumaine (N-methylgulcaine), lysine and procaine.
  • pharmaceutically acceptable solvate which, however, includes a solvent, water and the like as the solvating medium.
  • dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, syrups, elixirs, gels, powders, magmas, lozenges, ointments, creams, pastes, plasters, lotions, discs, suppositories, nasal or oral sprays, aerosols and the like. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desirable, tablets may be coated by standard aqueous or nonaqueous techniques.
  • Another preferred dosage form is as liquid or solution, comprising the active ingredients along with any additional optional ingredient or ingredients in a pharmaceutically acceptable carrier which is preferably a liquid.
  • compositions for use in the methods of the present invention may be prepared by any of the methods of pharmacy, but all methods include the step or steps of bringing into association the active ingredients and any optional ingredient or ingredients, carrier and the like.
  • the compositions are prepared by uniformly and intimately admixing the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
  • a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • composition containing loratadine and betamethasone for a tablet and preparation of a tablet by a compression molding process may be illustrated as in the following Table I:
  • Loratadine 2-10 Lactose monohydrate (LACTOSE FASTFLO ® ) 55-290
  • Tablet weight 60-300 mg.
  • ingredients may be admixed in any suitable order and converted into a tablet by suitable methods such as, for example, the methods stated earlier.
  • betamethasone (0.25 mg) and loratadine (5 mg) were premixed with one portion (70 mg) of Lactose FASTFLO ® (available from Foremost Farm USA, Baraboo, Wisconsin).
  • Lactose FASTFLO ® available from Foremost Farm USA, Baraboo, Wisconsin.
  • the mix was then passed through a Quadro CoMil ® mill (a sieve mill available from Quadro, Waterloo, Ontario, Canada) equipped with a 20 mesh screen.
  • lactose FASTFLO ® 71.75 mg
  • croscarmellose sodium (2 mg) were then added and blended.
  • AVICEL PH301 ® is a microcrystalline cellulose, available from FMC Corporation Pharmaceutical Division, City of Industry, California; Kollidon VA64 ® is a modified polyvinyl pyrrolidone available from BASF
  • Cellulose microcrystalline e.g., AVICEL PH301 ®
  • AVICEL PH301 ® 55-290 Kollidon VA64 ® 1-5 Kollidon CL ® 2-10
  • loratadine 5 mg
  • betamethasone 0.25 mg
  • Kollidon VA64 ® 3 mg
  • cellulose 84.65 mg
  • Kollidon CL ® 7 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte à des compositions et à des procédés pour traiter la dermatite atopique, l'angio-oedème, l'urticaire, la rhinite allergique et d'autres troubles de ce type. Ces compositions comprennent des quantités thérapeutiquement efficaces d'antihistamines, par exemple de la loratadine, et de glucocorticoïdes, par exemple le bétaméthasone, pour un tel traitement.
EP99912236A 1999-03-01 1999-03-01 Compositions et methodes pour le traitement de la dermatite atopique, de l'angiooedeme et d'autres affections par l'emploi d'antihistaminiques et de glucocorticosteroides Withdrawn EP1049471A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/004502 WO2000051605A1 (fr) 1999-03-01 1999-03-01 Compositions et procedes pour traiter la dermatite atopique, l'angio-oedeme et autres troubles, en utilisant des antihistamines et des glucocorticoides

Publications (1)

Publication Number Publication Date
EP1049471A1 true EP1049471A1 (fr) 2000-11-08

Family

ID=22272279

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99912236A Withdrawn EP1049471A1 (fr) 1999-03-01 1999-03-01 Compositions et methodes pour le traitement de la dermatite atopique, de l'angiooedeme et d'autres affections par l'emploi d'antihistaminiques et de glucocorticosteroides

Country Status (4)

Country Link
EP (1) EP1049471A1 (fr)
JP (1) JP2001510485A (fr)
AU (1) AU3065299A (fr)
WO (1) WO2000051605A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2383970A1 (fr) * 1999-10-08 2001-04-19 Schering Corporation Traitement nasal topique
CA2513731A1 (fr) * 2003-02-10 2004-08-19 Novartis Ag Combinaisons pharmaceutiques contenant des corticoides et des immunodepresseurs pour traiter des maladies resistant aux inhibiteurs de corticoides et/ou de la calcineurine
DE10330243A1 (de) * 2003-07-03 2005-01-20 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von Arzneimitteln zur äusserlichen Behandlung der Neurodermitis
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
NZ588373A (en) * 2004-05-19 2012-01-12 Emisphere Tech Inc Topical cromolyn formulations
US20070003557A1 (en) * 2005-04-21 2007-01-04 Andres Forero Method for treating cancer using premedication
WO2008148572A1 (fr) * 2007-06-08 2008-12-11 Bayer Consumer Care Ag Combinaisons de principes actifs anti-inflammatoires pour le traitement de maladies de la peau et des muqueuses
US20090136430A1 (en) * 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis
AR077101A1 (es) * 2009-06-16 2011-08-03 Schering Corp Esteroides de heteroarilo (3,2-c), como agonistas de receptor glucocorticoide, composiciones y usos de los mismos
BR102012030828A2 (pt) 2012-12-03 2014-09-16 Ems Sa Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso
US20240024307A1 (en) 2020-12-04 2024-01-25 Laboratorios Silanes S.A. De C.V. Pharmaceutical combination of a corticosteroid and an antihistamine for the treatment and control of the inflammatory component of allergic processes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE223202T1 (de) * 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
EP0780127A1 (fr) * 1995-12-19 1997-06-25 The Procter & Gamble Company Pulvérisateur nasale contenant un stéréoide et un antihistamine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0051605A1 *

Also Published As

Publication number Publication date
JP2001510485A (ja) 2001-07-31
WO2000051605A1 (fr) 2000-09-08
AU3065299A (en) 2000-09-21

Similar Documents

Publication Publication Date Title
US7923441B2 (en) Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application
JP2012001558A (ja) ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物
US4945089A (en) Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids
US20030191096A1 (en) Method of hormonal therapy
EP1049471A1 (fr) Compositions et methodes pour le traitement de la dermatite atopique, de l'angiooedeme et d'autres affections par l'emploi d'antihistaminiques et de glucocorticosteroides
JP2005526843A (ja) 電気痙攣療法（「ｅｃｔ」）に対する治療応答を増大させるための方法
US6423721B1 (en) Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US7776846B2 (en) Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application
EP1558265A1 (fr) Protection cardiovasculaire a l'aide de progestines anti-aldosteroniques
JP5278313B2 (ja) 輸送体増強コルチコステロイド活性
JP2011506607A (ja) 免疫炎症性障害の処置のための治療法
AU2016294185B2 (en) Estrogen receptor β partial agonist having estrogen receptor α inhibitory effect, and therapeutic agent for gynecological disorders using same
US7786101B2 (en) Cardiovascular protection using anti-aldosteronic progestins
US5358943A (en) Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids
MXPA99002272A (en) Compositions and methods for the treatment of atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoi
US20020028793A1 (en) Use of estrogens and delta-gonadien-21-3,20-diones
WO2000015226A1 (fr) Anti-histamines traitant la sinusite ou l'otite moyenne non infectieuse
CN101987103A (zh) 一种碳酸酐酶抑制剂的眼用组合物
CN101987104A (zh) 一种杂芳香基氨磺酰基羧酸酯碳酸酐酶抑制剂的眼用组合物
JP2002543136A (ja) 併用療法における抗プロゲスタゲンの使用
HO et al. ADRENALINE ANALOGUES
EP0966289A1 (fr) Budesonide pour le traitement d'affections hepatiques cholestatiques
JPH03275624A (ja) 新規な皮膚潰瘍治療剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990428

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 19990428;LV PAYMENT 19990428;RO PAYMENT 19990428

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MICHEL, OLIVIER

Inventor name: ARELLANO, SERGIO MORALES

Inventor name: RAMOS, JOSE VILLACAMPA

Inventor name: LUGO, SERGIO ULLOA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021001

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1028736

Country of ref document: HK